
Edoardo Fabini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1767282/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A SMYD3 Smallâ€Molecule Inhibitor Impairing Cancer Cell Growth. Journal of Cellular Physiology, 2015, 230, 2447-2460.	4.1	95
2	Monitoring drug–serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. Journal of Pharmaceutical and Biomedical Analysis, 2017, 144, 188-194.	2.8	37
3	Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends. Future Medicinal Chemistry, 2019, 11, 901-921.	2.3	29
4	Determination of levamisole and tetramisole in seized cocaine samples by enantioselective high-performance liquid chromatography and circular dichroism detection. Journal of Chromatography A, 2014, 1363, 150-154.	3.7	21
5	Surface plasmon resonance and circular dichroism characterization of cucurbitacins binding to serum albumins for early pharmacokinetic profiling. Journal of Pharmaceutical and Biomedical Analysis, 2016, 122, 166-172.	2.8	20
6	Surface plasmon resonance and isothermal titration calorimetry to monitor the Ni(II)-dependent binding of Helicobacter pylori NikR to DNA. Analytical and Bioanalytical Chemistry, 2016, 408, 7971-7980.	3.7	14
7	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. IScience, 2020, 23, 101604.	4.1	14
8	Combination of human acetylcholinesterase and serum albumin sensing surfaces as highly informative analytical tool for inhibitor screening. Journal of Pharmaceutical and Biomedical Analysis, 2018, 155, 177-184.	2.8	12
9	Unveiling the Biochemistry of the Epigenetic Regulator SMYD3. Biochemistry, 2019, 58, 3634-3645.	2.5	8
10	Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase. ChemBioChem, 2021, 22, 1597-1608.	2.6	8
11	Stoppedâ€Flow Enantioselective HPLCâ€CD Analysis and TDâ€DFT Stereochemical Characterization of Methyl <i>Trans</i> â€3â€(3,4â€Dimethoxyphenyl)Glycidate. Chirality, 2015, 27, 914-918.	2.6	6
12	Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. SSRN Electronic Journal, 0, , .	0.4	0